# Molecular Biology and Cancer Genetics Research Program (MBCG)

> **NIH NIH P30** · OHIO STATE UNIVERSITY · 2020 · $48,693

## Abstract

PROJECT-003: MOLECULAR BIOLOGY AND CANCER GENETICS PROGRAM (MBCG) 
PROJECT SUMMARY / ABSTRACT 
The Molecular Biology & Cancer Genetics (MBCG) Program at The Ohio State University Comprehensive 
Cancer Center (OSUCCC), led by Michael Ostrowski, PhD and Matthew Ringel, MD, unites a highly 
productive, collaborative and cancer focused team of 44 basic and translational scientists representing 7 
colleges and 18 academic departments at The Ohio State University. Program science is centered in four 
major cancer-focused scientific themes: small non-coding RNAs and cancer, human cancer 
genetics/genomics, signal transduction and therapeutic resistance, and tumor microenvironment. Program 
members utilize state-of-the-art approaches to 1) identify genes and pathways that fuel tumor cell initiation and 
growth, and 2) provide mechanistic details of how these genes and pathways contribute to tumor progression 
and therapeutic resistance. Our overall goal is to define the mechanisms that account for the association 
between genes and cancer and to exploit this knowledge in order to reduce the incidence of death from 
cancer. 
The Specific Aims of the MBCG Program are: 1) to identify human genes, including non-coding genes such as 
those encoding microRNAs, that either through direct mutations or epigenetic mechanisms, result in an 
increased predisposition to cancer; 2) to determine the molecular mechanisms underlying the expression and 
function of the genes contributing to normal development, cancer progression, and therapeutic resistance; 3) to 
utilize the knowledge gained from gene identification and gene functions in tumorigenesis in order to reduce 
the incidence of death from cancer. 
During the prior funding period of the OSUCCC P30 CCSG, MBCG Program members published 810 research 
papers, including 104 high impact (> 10) manuscripts in journals such as Cell, Cancer Cell, Science, Nature 
Medicine, Nature Cell Biology, Journal of Clinical Oncology, and Journal of Clinical Investigation. 
There is extensive collaboration, with 21% intra-programmatic, 31% inter-programmatic, and 66% multi- 
institutional publications. Overall, 81% of MBCG publications are collaborative. MBCG Program members are 
principal investigators (PIs) on seven NCI programmatic grants, including a P01 and U01 in breast cancer (P01 
CA097189, U01 CA154200), a P01 and P50 SPORE in thyroid cancer (P01 CA124570, P50 CA168505), a 
P01 in epigenetics (CA129242) and two U01s in lung cancer (U01 CA152758, U01 CA166905). They are PIs 
on CCSG-approved grants whose direct funding is currently $9.39 million, with $7.5 million in NCI funding 
(80% of total CCSG-approved funding). Program members are principal investigators on 21 active protocols 
that have accrued 5760 patients over the past five years. MBCG studies are predominantly interventional but 
non-therapeutic, and non-interventional as most of our interventional therapeutic work is accomplished 
collaboratively within the Trans...

## Key facts

- **NIH application ID:** 9843883
- **Project number:** 5P30CA016058-44
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Michael C. Ostrowski
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $48,693
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9843883

## Citation

> US National Institutes of Health, RePORTER application 9843883, Molecular Biology and Cancer Genetics Research Program (MBCG) (5P30CA016058-44). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9843883. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*